We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rapid Diagnosis of Myocardial Infarction within Six Hours
News

Rapid Diagnosis of Myocardial Infarction within Six Hours

Rapid Diagnosis of Myocardial Infarction within Six Hours
News

Rapid Diagnosis of Myocardial Infarction within Six Hours

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Rapid Diagnosis of Myocardial Infarction within Six Hours"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Randox have developed a multi marker Cardiac biochip array for rapid diagnosis of myocardial infarction (MI) and identification of at risk acute coronary syndrome (ACS) patients. This array simultaneously and quantitatively tests four cardiac biomarkers using a single patient sample within the critical 3-6 hour post pain onset treatment window.

The Randox Cardiac Array combines the gold standard Troponin test with CK-MB, Myoglobin and heart Fatty Acid Binding Protein (h-FABP). h-FABP is gaining a reputation as an ischaemic indicator and as an early marker of cardiac muscle damage. As a single marker, h-FABP has been shown to be a identifier of high risk MI patients, independent of Troponin.

As a multi-analyte test, the Cardiac Biochip Array provides greater diagnostic performance, with 20% increased sensitivity compared to testing Troponin alone and a 98% rule out for MI within 3-6 hours of pain onset. This means that cardiac patients requiring intervention are given immediate priority and that non-MI patients can be quickly managed, the company says.

The Randox biochip array technology is based on familiar ELISA principles, with the Cardiac Array utilizing sandwich chemiluminescent immunoassays. Three biochip analyzers are available; the fully automated, high throughput Evidence, the semi automated medium volume Investigator and the new, fully automated Multistat.

Using advanced technology, the Multistat is near-patient biochip platform providing laboratory-quality results in 20 minutes. All Randox biochip analyzers are suitable for a comprehensive range of biochip arrays, providing a multi-analyte solution to clinical and research needs.

To complement the clinical Cardiac array, Randox also offer an expanded research array - Cardiac Plus. In addition to the four markers on the Cardiac biochip, Cardiac Plus contains Glycogen Phosphorylase BB and Carbonic Anhydrase III. This combination has already found utility in sports medicine, for example, where elite athletes can monitor cardiac stress during and post-endurance competitions.
Advertisement